Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 April 2024 | Story André Damons | Photo Stephen Collett
Prof Salim Karim
Prof Francis Petersen, Vice-Chancellor and Principal of the University of the Free State (left) and Prof Gert Van Zyl, Faculty of Health Sciences Dean (right) conferred Prof Salim S Abdool Karim honorary doctorate for his ground-breaking research in AIDS and COVID-19. He received the degree PhD in Medical Virology (h.c.) during the Faculty of Health Sciences graduation ceremony.

With the case study of Caprise 256, a young woman in his AIDS study, and her potent antibody that kills HIV, Prof Salim S Abdool Karim, honorary doctorate recipient, conveyed the message of the power of science, knowledge and discovery to motivate the graduates from the Faculties of Health Sciences and Theology and Religion at the University of the Free State (UFS).

Prof Karim, renowned for his ground-breaking research in AIDS and COVID-19, received the degree PhD in Medical Virology (h.c.) during Thursday’s (18 April 2024) graduation ceremony.

From humble beginnings

“It is great honour and privilege to be here and accept this honorary doctorate. I first went to university in 1978 and wanted to study engineering but did not have the money to pay for registration as I come from a poor background. So, I attended classes anywhere. But then I was accepted to study medicine at the University of Natal with a full scholarship and that was the end of my career in engineering.

“From that humble beginning to today where you might have watched me on TV trying to share with you what we know about COVID-19 and other infectious diseases, is a great culmination of a career and I am deeply honoured and privileged to receive this honorary doctorate”, he said shortly after accepting his fifth honorary degree.

Prof Abdool Karim, a clinical infectious disease epidemiologist who is widely recognised for scientific contributions to AIDS and COVID-19, also shared with graduates the last 20 years of his academic journey with an example to illustrate how exciting the acquisition of knowledge and thrill of discovery can be. He talked about his work with AIDS and says it remains one of the world’s greatest challenges. Last year, he said, there were 1.3 million new infections and over 700 000 deaths as a result of AIDS.

Caprisa 256’s antibody

“I have devoted almost 40 years of research to looking for solutions for the AIDS problem and one of the biggest problems we are dealing with is the high rate of HIV, particularly in young girls. In 2003 we started a study to begin to understand why young women are at such a high risk of HIV.

“We enrolled hundreds of young women without HIV. We provided them with all kinds of knowledge to try and keep them HIV-free. Amongst those women we enrolled was participant 256, a young lady and she acquired HIV infection two years later in 2005.”

It would later turn out that this young woman, codename Caprisa 256, has a very special antibody – the kind that can kill a wide range of HIV – which is referred to as a broadly neutralising antibody. It is an antibody researchers tried to ellicit in making vaccine.

It turned out that not only is her antibody able to kill a wide range of HIV, it is a highly potent antibody. After testing and cloning a cell in the blood and growing it in a culture and harvesting the antibody, it was genetically manipulated to get a better antibody.

The Director of the Centre for the AIDS Programme of Research in South Africa (Caprisa), explained that it took two-and-a-half years to manufacture this antibody in the US and the first South African was injected with it in 2020. They enrolled over 1 000 women in a study with half of the women receiving the placebo and half the antibody. The question whether it works, or protects humans from the HIV will only be answered next year, Prof Abdool Karim explained. 

The 3 Ps

“What I am trying to convey to you, it’s the power of science, the power of knowledge, the power of discovery and when each of you goes out into the world, I want to leave you with the message that there are three valuable lessons that I have learned in this 20-year journey of Caprisa 256.

“The first one is find your passion, find something that excites you when you wake up in the morning. There will be people that would want to pull you down, you will have to stand firm. You have to show that you are passionate and committed and regardless of the obstacles, you will persevere. Find your passion and persevere. And as you do that, always remember the pursuit of excellence. I know that each of you will bring to this world your own humanity, your own values, and we are in this world, in a situation where we are in desperate need of people who will bring their humanity and their wisdom to bear.”

Prof Francis Petersen, Vice-Chancellor and Principal of the UFS, congratulated Prof Abdool Karim on his honorary degree and praised his groundbreaking research on Aids and COVID-19, as well as his exceptional work in medical virology over the years. “Prof Abdool Karim led the South African response to COVID-19, providing us as the public, as well as the government with scientific advice on the virus, new variants, and flattening the curve. Prof Abdool Karim has the ability to easily explain complex science to members of the general public in such a way that they are able to understand it. He played a critical role during the pandemic, and for this as well as for his research on Aids, South Africa is indebted to him.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept